Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Boettcher, Steffen"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 68
Tytuł:
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
Autorzy:
Mueller, Jan
Schimmer, Roman R
Koch, Christian
Schneiter, Florin
Fullin, Jonas
Lysenko, Veronika
Pellegrino, Christian
Klemm, Nancy
Russkamp, Norman
Myburgh, Renier
Volta, Laura
Theocharides, Alexandre PA
Kurppa, Kari J
Ebert, Benjamin L
Schroeder, Timm
Manz, Markus G
Boettcher, SteffenAff1, IDs44321024000242_cor17
Pokaż więcej
Źródło:
EMBO Molecular Medicine. 16(3):445-474
Czasopismo naukowe
Szczegóły
Tytuł:
Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
Autorzy:
Carter, Bing Z.Aff1, IDs4140802300830w_cor1
Mak, Po Yee
Tao, Wenjing
Ayoub, Edward
Ostermann, Lauren B.
Huang, Xuelin
Loghavi, Sanam
Boettcher, Steffen
Nishida, Yuki
Ruvolo, Vivian
Hughes, Paul E.
Morrow, Phuong K.
Haferlach, Torsten
Kornblau, Steven
Muftuoglu, Muharrem
Andreeff, MichaelAff1, IDs4140802300830w_cor16
Pokaż więcej
Źródło:
Blood Cancer Journal. 13(1)
Czasopismo naukowe
Szczegóły
Tytuł:
Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
Autorzy:
Carter, Bing Z.Aff1, IDs4140802300857z_cor1
Mak, Po Yee
Tao, Wenjing
Ayoub, Edward
Ostermann, Lauren B.
Huang, Xuelin
Loghavi, Sanam
Boettcher, Steffen
Nishida, Yuki
Ruvolo, Vivian
Hughes, Paul E.
Morrow, Phuong K.
Haferlach, Torsten
Kornblau, Steven
Muftuoglu, Muharrem
Andreeff, MichaelAff1, IDs4140802300857z_cor16
Pokaż więcej
Źródło:
Blood Cancer Journal. 13(1)
Czasopismo naukowe
Szczegóły
Tytuł:
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1
Autorzy:
Fiskus, Warren
Mill, Christopher P.
Birdwell, Christine
Davis, John A.
Das, Kaberi
Boettcher, Steffen
Kadia, Tapan M.
DiNardo, Courtney D.
Takahashi, Koichi
Loghavi, Sanam
Soth, Michael J.
Heffernan, Tim
McGeehan, Gerard M.
Ruan, Xinjia
Su, Xiaoping
Vakoc, Christopher R.
Daver, Naval
Bhalla, Kapil N.Aff1, IDs41408023008266_cor18
Pokaż więcej
Źródło:
Blood Cancer Journal. 13(1)
Czasopismo naukowe
Szczegóły
Tytuł:
Enhanced TP53 reactivation disrupts MYC transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
Autorzy:
Yuki Nishida
Ishizawa, Jo
Ayoub, Edward
Montoya, Rafael Heinz
Ostermann, Lauren B.
Muftuoglu, Muharrem
Ruvolo, Vivian R.
Patsilevas, Tallie
Scruggs, Darah A.
Shayaun Khazaei
Po Yee Mak
Wenjing Tao
Carter, Bing Z.
Boettcher, Steffen
Ebert, Benjamin L.
Daver, Naval G.
Konopleva, Marina
Takahiko Seki
Kensuke Kojima
Andreeff, Michael
Pokaż więcej
Źródło:
Science Advances. 12/1/2023, Vol. 9 Issue 48, p1-18. 18p.
Czasopismo naukowe
Szczegóły
Tytuł:
3127 – MODELING PREDISPOSED AND SPORADIC CLONAL HEMATOPOIESIS USING INDUCED PLURIPOTENT STEM CELLS
Autorzy:
Rowe, Grant
Marion, William
Boettcher, Steffen
da Rocha, Edroaldo Lummertz
Ruiz-Torres, Sonya
Sensharma, Prerana
Tang, Yang
Kubaczka, Caroline
Lundin, Vanessa
Chao, Stephanie
Zhao, Anna
Sousa, Patricia
Ebert, Benjamin
North, Trista
Schlaeger, Thorsten
Wells, Susanne
Daley, George
Pokaż więcej
Źródło:
In Experimental Hematology August 2020 88 Supplement:S77-S77
Czasopismo naukowe
Szczegóły
Tytuł:
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.
Autorzy:
Boettcher S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Miller PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Sharma R; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
McConkey M; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Leventhal M; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Krivtsov AV; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Giacomelli AO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.; The Campbell Family Institute for Breast Cancer Research, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2M9, Canada.
Wong W; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Kim J; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Chao S; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.; Department of Biomedical Informatics, Harvard University, Boston, MA 02115, USA.
Kurppa KJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Yang X; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
Milenkowic K; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
Piccioni F; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
Root DE; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
Rücker FG; Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany.
Flamand Y; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Neuberg D; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lindsley RC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
Jänne PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.
Jacks T; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.; Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Döhner H; Department of Internal Medicine III, University of Ulm, 89081 Ulm, Germany.
Armstrong SA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ebert BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. benjamin_.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02142, USA.; Division of Hematology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Howard Hughes Medical Institute, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2019 Aug 09; Vol. 365 (6453), pp. 599-604.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Mutation, Missense*
Selection, Genetic*
Leukemia, Myeloid, Acute/*genetics
Tumor Suppressor Protein p53/*genetics
Animals ; CRISPR-Cas Systems ; Gain of Function Mutation ; Genes, Dominant ; Humans ; K562 Cells ; Mice ; Mice, Inbred C57BL ; Mice, Knockout
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 68

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies